1. Statin loading before coronary artery bypass grafting: a randomized trial.
- Author
-
Liakopoulos, Oliver J, Kuhn, Elmar W, Hellmich, Martin, Schlömicher, Markus, Strauch, Justus, Reents, Wilko, Diegeler, Anno, Thielmann, Matthias, Wendt, Daniel, Börgermann, Jochen, Gummert, Jan F, Stoppe, Christian, Goetzenich, Andreas, Martens, Sven, Reichenspurner, Hermann, Wippermann, Jens, Reuter, Hannes, Choi, Yeong-Hoon, Wahlers, Thorsten, and Investigators, for the StaRT-CABG
- Subjects
CORONARY artery bypass ,REVASCULARIZATION (Surgery) ,STATINS (Cardiovascular agents) ,MYOCARDIAL injury ,MYOCARDIAL infarction ,DRUG-eluting stents - Abstract
Aims Evidence suggests that a high-dose statin loading before a percutaneous coronary revascularization improves outcomes in patients receiving long-term statins. This study aimed to analyse the effects of such an additional statin therapy before surgical revascularization. Methods and results This investigator-initiated, randomized, double-blind, and placebo-controlled trial was conducted from November 2012 to April 2019 at 14 centres in Germany. Adult patients (n = 2635) with a long-term statin treatment (≥30 days) who were scheduled for isolated coronary artery bypass grafting (CABG) were randomly assigned to receive a statin-loading therapy or placebo at 12 and 2 h prior to surgery using a web-based system. The primary outcome of major adverse cardiac and cerebrovascular events (MACCE) was a composite consisting of all-cause mortality, myocardial infarction (MI), and a cerebrovascular event occuring within 30 days after surgery. Key secondary endpoints included a composite of cardiac death and MI, myocardial injury, and death within 12 months. Non-statistically relevant differences were found in the modified intention-to-treat analysis (2406 patients; 1203 per group) between the statin (13.9%) and placebo groups (14.9%) for the primary outcome [odds ratio (OR) 0.93, 95% confidence interval (CI) 0.74–1.18; P = 0.562] or any of its individual components. Secondary endpoints including cardiac death and MI (12.1% vs. 13.5%; OR 0.88, 95% CI 0.69–1.12; P = 0.300), the area under the troponin T-release curve (median 0.398 vs. 0.394 ng/ml, P = 0.333), and death at 12 months (3.1% vs. 2.9%; P = 0.825) were comparable between treatment arms. Conclusion Additional statin loading before CABG failed to reduce the rate of MACCE occuring within 30 days of surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF